From antimicrobial to anticancer peptides. A review

Frontiers in Microbiology

Volumn 4, Issue OCT, 2013, Pages

  Gaspar, Diana ^a   Salome Veiga A ^a   Castanho, Miguel A R B ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Anticancer peptides; Apoptosis induction; Drug development; Electrostatic interactions; Membrane disruption; Necrosis; Tumor selectivity

Indexed keywords

ANTINEOPLASTIC AGENT; BH3 PROTEIN; CECROPIN; DERMASEPTIN; ESTROGEN RECEPTOR ALPHA; GELATINASE A; GELATINASE B; HEPCIDIN; LACTOFERRICIN B; MAGAININ DERIVATIVE; MATRIX METALLOPROTEINASE; PEPTIDE; POLYPEPTIDE ANTIBIOTIC AGENT; REACTIVE OXYGEN METABOLITE; TACHYPLESIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CARCINOGENESIS; CELL DAMAGE; CELL DEATH; CELL DISRUPTION; CELL GROWTH; CELL KILLING; CELL MEMBRANE PERMEABILITY; CELL SWELLING; CYCLIZATION; CYTOTOXICITY; GENE EXPRESSION; HUMAN; HYDROPHOBICITY; IC 50; IMMUNOGENICITY; LEUKEMIA; LYMPHOMA; MYELOMA; NONHUMAN; REVIEW; SOLID TUMOR; STATIC ELECTRICITY; SURFACE CHARGE; TUMOR NECROSIS; UPREGULATION;

EID: 84885416827     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2013.00294     Document Type: Review

References (163)

1. Al-Benna, S., Shai, Y., Jacobsen, F., and Steinstraesser, L. (2011). Oncolytic activities of host defense peptides. Int. J. Mol. Sci. 12, 8027-8051. doi: 10.3390/ijms12118027
2. Albrethsen, J., Bogebo, R., Gammeltoft, S., Olsen, J., Winther, B., and Raskov, H. (2005). Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study. BMC Cancer 5:8. doi: 10.1186/1471-2407-5-8
3. Albrethsen, J., Moller, C. H., Olsen, J., Raskov, H., and Gammeltoft, S. (2006). Human neutrophil peptides 1, 2 and 3 are biochemical markers for metastatic colorectal cancer. Eur. J. Cancer 42, 3057-3064. doi: 10.1016/j.ejca.2006.05.039
4. Al-Hajj, M., and Clarke, M. F. (2004). Self-renewal and solid tumor stem cells. Oncogene 23, 7274-7282. doi: 10.1038/sj.onc.1207947
5. Alvarez-Calderon, F., Gregory, M. A., and Degregori, J. (2013). Using functional genomics to overcome therapeutic resistance in hematological malignancies. Immunol. Res. 55, 100-115. doi: 10.1007/s12026-012-8353-z
6. Alves, C. S., Melo, M. N., Franquelim, H. G., Ferre, R., Planas, M., Feliu, L., et al. (2010). Escherichia coli Cell Surface Perturbation and Disruption Induced by Antimicrobial Peptides BP100 and pepR. J. Biol. Chem. 285, 27536-27544. doi: 10.1074/jbc.M110.130955
7. Arap, W., Pasqualini, R., and Ruoslahti, E. (1998). Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279, 377-380. doi: 10.1126/science.279.5349.377
8. Arouri, A., Dathe, M., and Blume, A. (2009). Peptide induced demixing in PG/PE lipid mixtures: a mechanism for the specificity of antimicrobial peptides towards bacterial membranes? Biochim. Biophys. Acta 1788, 650-659. doi: 10.1016/j.bbamem.2008.11.022
9. Ausbacher, D., Svineng, G., Hansen, T., and Strom, M. B. (2012). Anticancer mechanisms of action of two small amphipathic beta(2,2)-amino acid derivatives derived from antimicrobial peptides. Biochim. Biophys. Acta 1818, 2917-2925. doi: 10.1016/j.bbamem.2012.07.005
10. Bateman, A., Singh, A., Jothy, S., Fraser, R., Esch, F., and Solomon, S. (1992). The levels and biologic action of the human neutrophil granule peptide Hp-1 in lung-tumors. Peptides 13, 133-139. doi: 10.1016/0196-9781(92)90152-S
11. Bechinger, B., and Lohner, K. (2006). Detergent-like actions of linear amphipathic cationic antimicrobial peptides. Biochim. Biophys. Acta 1758, 1529-1539. doi: 10.1016/j.bbamem.2006.07.001
12. Berge, G., Eliassen, L. T., Camilio, K. A., Bartnes, K., Sveinbjornsson, B., and Rekdal, O. (2010). Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide. Cancer Immunol. Immunother. 59, 1285-1294. doi: 10.1007/s00262-010-0857-6
13. Bitton, R. J., Guthmann, M. D., Gabri, M. R., Carnero, A. J. L., Alonso, D. F., Fainboim, L., et al. (2002). Cancer vaccines: an update with special focus on ganglioside antigens (review). Oncol. Rep. 9, 267-276.
14. Bowdish, D. M. E., Davidson, D. J., and Hancock, R. E. W. (2005). A re-evaluation of the role of host defence peptides in mammalian immunity. Curr. Protein Pept. Sci. 6, 35-51. doi: 10.2174/1389203053027494
15. Brandenburg, L. O., Merres, J., Albrecht, L. J., Varoga, D., and Pufe, T. (2012). Antimicrobial peptides: multifunctional drugs for different applications. Polymers 4, 539-560. doi: 10.3390/polym4010539
16. Brogden, K. A. (2005). Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nature Rev. Microbiol. 3, 238-250. doi: 10.1038/nrmicro1098
17. Brown, J. M., and Giaccia, A. J. (1998). The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58, 1408-1416.
18. Byrne, C., Khemtemourian, L., Pelekanou, V., Kampa, M., Leclercq, G., Sagan, S., et al. (2012). ERalpha17p, a peptide reproducing the hinge region of the estrogen receptor alpha associates to biological membranes: a biophysical approach. Steroids 77, 979-987. doi: 10.1016/j.steroids.2012.02.022
19. Chan, D. I., Prenner, E. J., and Vogel, H. J. (2006). Tryptophan- and arginine-rich antimicrobial peptides: structures and mechanisms of action. Biochim. Biophys. Acta 1758, 1184-1202. doi: 10.1016/j.bbamem.2006.04.006
20. Chan, S. C., Hui, L., and Chen, H. M. (1998). Enhancement of the cytolytic effect of anti-bacterial cecropin by the microvilli of cancer cells. Anticancer Res. 18, 4467-4474.
21. Chaudhary, J., and Munshi, M. (1995). Scanning electron-microscopic analysis of breast aspirates. Cytopathology 6, 162-167. doi: 10.1111/j.1365-2303.1995.tb00469.x
22. Chen, C. X., Hu, J., Zhang, S. Z., Zhou, P., Zhao, X. C., Xu, H., et al. (2012). Molecular mechanisms of antibacterial and antitumor actions of designed surfactant-like peptides. Biomaterials 33, 592-603. doi: 10.1016/j.biomaterials.2011.09.059
23. Chen, J. G., Xu, X. N., Underhfll, C. B., Yang, S. M., Wang, L. P., Chen, Y. X., et al. (2005). Tachyplesin activates the classic complement pathway to kill tumor cells. Cancer Res. 65, 4614-4622. doi: 10.1158/0008-5472.CAN-04-2253
24. Chen, J. Y., Lin, W. J., and Lin, T. L. (2009). A fish antimicrobial peptide, tilapia hepcidin TH2-3, shows potent antitumor activity against human fibrosarcoma cells. Peptides 30, 1636-1642. doi: 10.1016/j.peptides.2009.06.009
25. Chen, Y., Xu, X., Hong, S., Chen, J., Liu, N., Underhill, C. B., et al. (2001). RGD-Tachyplesin inhibits tumor growth. Cancer Res. 61, 2434-2438.
26. Cociancich, S., Ghazi, A., Hetru, C., Hoffmann, J. A., and Letellier, L. (1993). Insect defensin, an inducible antibacterial peptide, forms voltage-dependent channels in micrococcus-luteus. J. Biol. Chem. 268, 19239-19245.
27. Coussens, L. M., Fingleton, B., and Matrisian, L. M. (2002). Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387-2392. doi: 10.1126/science.1067100
28. Coussens, L. M., and Werb, Z. (2002). Inflammation and cancer. Nature 420, 860-867. doi: 10.1038/nature01322
29. Cruciani, R. A., Barker, J. L., Zasloff, M., Chen, H. C., and Colamonici, O. (1991). Antibiotic magainins exert cytolytic activity against transformed-cell lines through channel formation. Proc. Natl. Acad. Sci. U.S.A. 88, 3792-3796. doi: 10.1073/pnas.88.9.3792
30. Davies, B., Waxman, J., Wasan, H., Abel, P., Williams, G., Krausz, T., et al. (1993). Levels of matrix metalloproteases in bladder-cancer correlate with tumor grade and invasion. Cancer Res. 53, 5365-5369.
31. Derrico, A., Garbisa, S., Liotta, L. A., Castronovo, V., Stetlerstevenson, W. G., and Grigioni, W. F. (1991). Augmentation of type-Iv collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast-carcinoma progression. Mod. Pathol. 4, 239-246.
32. Destouches, D., Huet, E., Sader, M., Frechault, S., Carpentier, G., Ayoul, F., et al. (2012). Multivalent pseudopeptides targeting cell surface nucleoproteins inhibit cancer cell invasion through tissue inhibitor of metalloproteinases 3 (TIMP-3) release. J. Biol. Chem. 287, 43685-43693. doi: 10.1074/jbc.M112.380402
33. Dobrzynska, I., Szachowicz-Petelska, B., Sulkowski, S., and Figaszewski, Z. (2005). Changes in electric charge and phospholipids composition in human colorectal cancer cells. Mol. Cell. Biochem. 276, 113-119. doi: 10.1007/s11010-005-3557-3
34. Domagala, W., and Koss, L. G. (1980). Surface configuration of human-tumor cells obtained by fine needle aspiration biopsy - comparative light microscopic and scanning electron-microscopic study. Acta Cytol. 24, 81-81.
35. Droin, N., Hendra, J. B., Ducoroy, P., and Solary, E. (2009). Human defensins as cancer biomarkers and antitumour molecules. J. Proteomics 72, 918-927. doi: 10.1016/j.jprot.2009.01.002
36. Dube, D. H., and Bertozzi, C. R. (2005). Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat. Rev. Drug Discov. 4, 477-488. doi: 10.1038/nrd1751
37. Dvorak, H. F., Flier, J., and Frank, H. (1986). Tumors - wounds that do not heal - similarities between tumor stroma generation and wound-healing. N. Engl. J. Med. 315, 1650-1659. doi: 10.1056/NEJM198612253152606
38. Edison, N., Reingewertz, T. H., Gottfried, Y., Lev, T., Zuri, D., Maniv, I., et al. (2012). Peptides mimicking the unique ARTS-XIAP binding site promote apoptotic cell death in cultured cancer cells. Clin. Cancer Res. 18, 2569-2578. doi: 10.1158/1078-0432.CCR-11-1430
39. Egeblad, M., and Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 161-174. doi: 10.1038/nrc745
40. Eliassen, L. T., Berge, G., Leknessund, A., Wikman, M., Lindin, I., Lokke, C., et al. (2006). The antimicrobial peptide, Lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo. Int. J. Cancer 119, 493-500. doi: 10.1002/ijc.21886
41. Ellerby, H. M., Lee, S., Ellerby, L. M., Chen, S., Kiyota, T., Del Rio, G., et al. (2003). An artificially designed pore-forming protein with anti-tumor effects. J. Biol. Chem. 278, 35311-35316. doi: 10.1074/jbc.M300474200
42. Elmore, S. (2007). Apoptosis: a review of programmed cell death. Toxicol. Pathol. 35, 495-516. doi: 10.1080/01926230701320337
43. Fadnes, B., Rekdal, O., and Uhlin-Hansen, L. (2009). The anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cells. BMC Cancer 9:183. doi: 10.1186/1471-2407-9-183
44. Fadnes, B., Uhlin-Hansen, L., Lindin, I., and Rekdal, O. (2011). Small lytic peptides escape the inhibitory effect of heparan sulfate on the surface of cancer cells. BMC Cancer 11:116. doi: 10.1186/1471-2407-11-116
45. Fazio, M. A., Jouvensal, L., Vovelle, F., Bulet, P., Miranda, M. T. M., Daffre, S., et al. (2007). Biological and structural characterization of new linear gomesin analogues with improved therapeutic indices. Biopolymers 88, 386-400. doi: 10.1002/bip.20660
46. Feliu, L., Oliveras, G., Cirac, A. D., Besalu, E., Roses, C., Colomer, R., et al. (2010). Antimicrobial cyclic decapeptides with anticancer activity. Peptides 31, 2017-2026. doi: 10.1016/j.peptides.2010.07.027
47. Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., and Parkin, D. M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893-2917. doi: 10.1002/ijc.25516
48. Fernebro, J. (2011). Fighting bacterial infections-future treatment options. Drug Resist. Updat. 14, 125-139. doi: 10.1016/j.drup.2011.02.001
49. Friedrich, C. L., Moyles, D., Beveridge, T. J., and Hancock, R. E. W. (2000). Antibacterial action of structurally diverse cationic peptides on gram-positive bacteria. Antimicrob. Agents Chemother. 44, 2086-2092. doi: 10.1128/AAC.44.8.2086-2092.2000
50. Furlong, S. J., Ridgway, N. D., and Hoskin, D. W. (2008). Modulation of ceramide metabolism in T-leukemia cell lines potentiates apoptosis induced by the cationic antimicrobial peptide bovine lactoferricin. Int. J. Oncol. 32, 537-544.
51. Gao, S., Hsieh, C. L., Bhansali, M., Kannan, A., and Shemshedini, L. (2013). A peptide against soluble guanylyl cyclase alpha1: a new approach to treating prostate cancer. PLoS ONE 8:e64189. doi: 10.1371/journal.pone.0064189
52. Gaspar, D., Veiga, A. S., Sinthuvanich, C., Schneider, J. P., and Castanho, M. A. R. B. (2012). Anticancer peptide SVS-1: efficacy precedes membrane neutralization. Biochemistry 51, 6263-6265. doi: 10.1021/bi300836r
53. Gatti, L., and Zunino, F. (2005). Overview of tumor cell chemoresistance mechanisms. Methods Mol. Med. 111, 127-148. doi: 10.1385/1-59259-889-7:127
54. Giuliani, A., Pirri, G., and Nicoletto, S. F. (2007). Antimicrobial peptides: an overview of a promising class of therapeutics. Cent. Eur. J. Biol. 2, 1-33. doi: 10.2478/s11535-007-0010-5
55. Gross, S., and Andra, J. (2012). Anticancer peptide NK-2 targets cell surface sulphated glycans rather than sialic acids. Biol. Chem. 393, 817-827. doi: 10.1515/hsz-2012-0136
56. Guo, Z. W., and Wang, Q. L. (2009). Recent development in carbohydrate-based cancer vaccines. Curr. Opin. Chem. Biol. 13, 608-617. doi: 10.1016/j.cbpa.2009.08.010
57. Hammami, R., and Fliss, I. (2010). Current trends in antimicrobial agent research: chemo- and bioinformatics approaches. Drug Discov. Today 15, 540-546. doi: 10.1016/j.drudis.2010.05.002
58. Hanai, N., Nakamura, K., and Shitara, K. (2000). Recombinant antibodies against ganglioside expressed on tumor cells. Cancer Chemother. Pharmacol. 46, S13-S17. doi: 10.1007/PL00014042
59. Hancock, R. E. W., and Diamond, G. (2000). The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol. 8, 402-410. doi: 10.1016/S0966-842X(00)01823-0
60. Hancock, R. E. W., and Sahl, H. G. (2006). Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24, 1551-1557. doi: 10.1038/nbt1267
61. Hansel, W., Enright, F., and Leuschner, C. (2007). Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo. Mol. Cell. Endocrinol. 260, 183-189. doi: 10.1016/j.mce.2005.12.056
62. Harris, F., Dennison, S. R., Singh, J., and Phoenix, D. A. (2011). On the selectivity and efficacy of defense peptides with respect to cancer cells. Med. Res. Rev. 33, 190-234. doi: 10.1002/med.20252
63. Harris, F., Dennison, S. R., Singh, J., and Phoenix, D. A. (2013). On the selectivity and efficacy of defense peptides with respect to cancer cells. Med. Res. Rev. 33, 190-234. doi: 10.1002/med.20252
64. Hilchie, A. L., Doucette, C. D., Pinto, D. M., Patrzykat, A., Douglas, S., and Hoskin, D. W. (2011). Pleurocidin-family cationic antimicrobial peptides are cytolytic for breast carcinoma cells and prevent growth of tumor xenografts. Breast Cancer Res. 13:R102. doi: 10.1186/bcr3043
65. Hoskin, D. W., and Ramamoorthy, A. (2008). Studies on anticancer activities of antimicrobial peptides. Biochim. Biophys. Acta 1778, 357-375. doi: 10.1016/j.bbamem.2007.11.008
66. Hu, J., Chen, C., Zhang, S., Zhao, X., Xu, H., and Lu, J. R. (2011). Designed antimicrobial and antitumor peptides with high selectivity. Biomacromolecules 12, 3839-3843. doi: 10.1021/bm201098j
67. Huang, Y. B., He, L. Y., Jiang, H. Y., and Chen, Y. X. (2012). Role of helicity on the anticancer mechanism of action of cationic-helical peptides. Int. J. Mol. Sci. 13, 6849-6862. doi: 10.3390/ijms13066849
68. Huang, Y. B., Wang, X. F., Wang, H. Y., Liu, Y., and Chen, Y. (2011). Studies on mechanism of action of anticancer peptides by modulation of hydrophobicity within a defined structural framework. Mol. Cancer Ther. 10, 416-426. doi: 10.1158/1535-7163.MCT-10-0811
69. Iwasaki, T., Ishibashi, J., Tanaka, H., Sato, M., Asaoka, A., Taylor, D., et al. (2009). Selective cancer cell cytotoxicity of enantiomeric 9-mer peptides derived from beetle defensins depends on negatively charged phosphatidylserine on the cell surface. Peptides 30, 660-668. doi: 10.1016/j.peptides.2008.12.019
70. Jaattela, M. (1995). Over-Expression of Hsp70 Confers Tumorigenicity to Mouse Fibrosarcoma Cells. Int. J. Cancer 60, 689-693. doi: 10.1002/ijc.2910600520
71. Janek, T., Krasowska, A., Radwanska, A., and Lukaszewicz, M. (2013). Lipopeptide Biosurfactant Pseudofactin II Induced Apoptosis of Melanoma A 375 Cells by Specific Interaction with the Plasma Membrane. PLoS ONE 8:e57991. doi: 10.1371/journal.pone.0057991
72. Jang, J. H., Kim, M. Y., Lee, J. W., Kim, S. C., and Cho, J. H. (2011). Enhancement of the cancer targeting specificity of buforin lib by fusion with an anionic peptide via a matrix metalloproteinases-cleavable linker. Peptides 32, 895-899. doi: 10.1016/j.peptides.2011.02.010
73. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J. Q., Smigal, C., et al. (2006). Cancer statistics, 2006. CA Cancer J. Clin. 56, 106-130. doi: 10.3322/canjclin.56.2.106
74. Jenssen, H., Andersen, J. H., Uhlin-Hansen, L., Gutteberg, T. J., and Rekdal, O. (2004). Anti-HSV activity of lactoferricin analogues is only partly related to their affinity for heparan sulfate. Antiviral Res. 61, 101-109. doi: 10.1016/j.antiviral.2003.09.001
75. Jerala, R., and Porro, M. (2004). Endotoxin neutralizing peptides. Curr. Top. Med. Chem. 4, 1173-1184. doi: 10.2174/1568026043388079
76. Johnstone, S. A., Gelmon, K., Mayer, L. D., Hancock, R. E., and Bally, M. B. (2000). In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Anticancer. Drug Des. 15, 151-160.
77. Kalyanaraman, B., Joseph, J., Kalivendi, S., Wang, S. W., Konorev, E., and Kotamraju, S. (2002). Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol. Cell. Biochem. 234, 119-124. doi: 10.1023/A:1015976430790
78. Kampa, M., Pelekanou, V., Gallo, D., Notas, G., Troullinaki, M., Pediaditakis, I., et al. (2011). ER alpha 17p, an ER alpha P-295-T-311 fragment, modifies the migration of breast cancer cells, through actin cytoskeleton rearrangements. J. Cell. Biochem. 112, 3786-3796. doi: 10.1002/jcb.23309
79. Kawamoto, M., Horibe, T., Kohno, M., and Kawakami, K. (2011). A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells. BMC Cancer 11:359. doi: 10.1186/1471-2407-11-359
80. Kim, S., Kim, S. S., Bang, Y. J., Kim, S. J., and Lee, B. J. (2003). In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines. Peptides 24, 945-953. doi: 10.1016/S0196-9781(03)00194-3
81. Koskimaki, J. E., Karagiannis, E. D., Rosca, E. V., Vesuna, F., Winnard, P. T., Raman, V., et al. (2009). Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts. Neoplasia 11, 1285-1291. doi: 10.1593/neo.09620
82. Kozlowska, K., Nowak, J., Kwiatkowski, B., and Cichorek, M. (1999). ESR study of plasmatic membrane of the transplantable melanoma cells in relation to their biological properties. Exp. Toxicol. Pathol. 51, 89-92. doi: 10.1016/S0940-2993(99)80074-8
83. Kuriyama, I., Miyazaki, A., Tsuda, Y., Yoshida, H., and Mizushina, Y. (2013). Inhibitory effect of novel somatostatin peptide analogues on human cancer cell growth based on the selective inhibition of DNA polymerase beta. Bioorg. Med. Chem. 21, 403-411. doi: 10.1016/j.bmc.2012.11.024
84. Labelle, J. L., Katz, S. G., Bird, G. H., Gavathiotis, E., Stewart, M. L., Lawrence, C., et al. (2012). A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. J. Clin. Invest. 122, 2018-2031. doi: 10.1172/JCI46231
85. Lee, E., Rosca, E. V., Pandey, N. B., and Popel, A. S. (2011). Small peptides derived from somatotropin domain-containing proteins inhibit blood and lymphatic endothelial cell proliferation, migration, adhesion and tube formation. Int. J. Biochem. Cell Biol. 43, 1812-1821. doi: 10.1016/j.biocel.2011.08.020
86. Lee, H. S., Park, C. B., Kim, J. M., Jang, S. A., Park, I. Y., Kim, M. S., et al. (2008). Mechanism of anticancer activity of buforin IIb, a histone H2A-derived peptide. Cancer Lett. 271, 47-55. doi: 10.1016/j.canlet.2008.05.041
87. Lemeshko, V. V. (2013). Electrical potentiation of the membrane permeabilization by new peptides with anticancer properties. Biochim Biophys Acta 1828, 1047-1056. doi: 10.1016/j.bbamem.2012.12.012
88. Leuschner, C., Enright, F. M., Gawronska, B., and Hansel, W. (2003). Membrane disrupting lytic peptide conjugates destroy hormone dependent and independent breast cancer cells in vitro and in vivo. Breast Cancer Res. Treat. 78, 17-27. doi: 10.1023/A:1022169525521
89. Leuschner, C., and Hansel, W. (2005). Targeting breast and prostate cancers through their hormone receptors. Biol. Reprod. 73, 860-865. doi: 10.1095/biolreprod.105.043471
90. Li, Y., Xiang, Q., Zhang, Q., Huang, Y., and Su, Z. (2012). Overview on the recent study of antimicrobial peptides: origins, functions, relative mechanisms and application. Peptides 37, 207-215. doi: 10.1016/j.peptides.2012.07.001
91. Li, Y. C., Park, M. J., Ye, S. K., Kim, C. W., and Kim, Y. N. (2006). Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am. J. Pathol. 168, 1107-1118. doi: 10.2353/ajpath.2006.050959
92. Lin, W. J., Chien, Y. L., Pan, C. Y., Lin, T. L., Chen, J. Y., Chiu, S. J., et al. (2009). Epinecidin-1, an antimicrobial peptide from fish (Epinephelus coioides) which has an antitumor effect like lytic peptides in human fibrosarcoma cells. Peptides 30, 283-290. doi: 10.1016/j.peptides.2008.10.007
93. Liu, S., Yang, H., Wan, L., Cheng, J., and Lu, X. (2013). Penetratin-mediated delivery enhances the antitumor activity of the cationic antimicrobial peptide magainin II. Cancer Biother. Radiopharm. 28, 289-297. doi: 10.1089/cbr.2012.1328
94. Lu, J., and Chen, Z. W. (2010). Isolation, characterization and anti-cancer activity of SK84, a novel glycine-rich antimicrobial peptide from Drosophila virilis. Peptides 31, 44-50. doi: 10.1016/j.peptides.2009.09.028
95. Ma, J. Y., Huang, F. F., Lin, H. L., and Wang, X. (2013). Isolation and purification of a peptide from bullacta exarata and its impaction of apoptosis on prostate cancer cell. Marine Drugs 11, 266-273. doi: 10.3390/md11010266
96. Mader, J. S., and Hoskin, D. W. (2006). Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opin. Investig. Drugs 15, 933-946. doi: 10.1517/13543784.15.8.933
97. Mader, J. S., Salsman, J., Conrad, D. M., and Hoskin, D. W. (2005). Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines. Mol. Cancer Ther. 4, 612-624. doi: 10.1158/1535-7163.MCT-04-0077
98. Maher, S., and McClean, S. (2008). Melittin exhibits necrotic cytotoxicity in gastrointestinal cells which is attenuated by cholesterol. Biochem. Pharmacol. 75, 1104-1114. doi: 10.1016/j.bcp.2007.10.029
99. Mai, J. C., Mi, Z. B., Kim, S. H., Ng, B., and Robbins, P. D. (2001). A proapoptotic peptide for the treatment of solid tumors. Cancer Res. 61, 7709-7712.
100. Maroti, G., Kereszt, A., Kondorosi, E., and Mergaert, P. (2011). Natural roles of antimicrobial peptides in microbes, plants and animals. Res. Microbiol. 162, 363-374. doi: 10.1016/j.resmic.2011.02.005
101. McKeown, S. T., Lundy, F. T., Nelson, J., Lockhart, D., Irwin, C. R., Cowan, C. G., et al. (2006). The cytotoxic effects of human neutrophil peptide-1 (HNP1) and lactoferrin on oral squamous cell carcinoma (OSCC) in vitro. Oral Oncol. 42, 685-690. doi: 10.1016/j.oraloncology.2005.11.005
102. McPhee, J. B., Scott, M. G., and Hancock, R. E. W. (2005). Design of host defence peptides for antimicrobial and immunity enhancing activities. Comb. Chem. High Throughput Screen. 8, 257-272. doi: 10.2174/1386207053764558
103. Mika, J. T., Moiset, G., Cirac, A. D., Feliu, L., Bardaji, E., Planas, M., et al. (2011). Structural basis for the enhanced activity of cyclic antimicrobial peptides: the case of BPC194. Biochim. Biophys. Acta 1808, 2197-2205. doi: 10.1016/j.bbamem.2011.05.001
104. Miyazaki, Y., Aoki, M., Yano, Y., and Matsuzaki, K. (2012). Interaction of antimicrobial peptide magainin 2 with gangliosides as a target for human cell binding. Biochemistry 51, 10229-10235. doi: 10.1021/bi301470h
105. Moore, A. J., Devine, D. A., and Bibby, M. C. (1994). Preliminary experimental anticancer activity of cecropins. Pept. Res. 7, 265-269.
106. Muller, C. A., Markovic-Lipkovski, J., Klatt, T., Gamper, J., Schwarz, G., Beck, H., et al. (2002). Human alpha-defensins HNPs-1, -2, and -3 in renal cell carcinoma: influences on tumor cell proliferation. Am. J. Pathol. 160, 1311-1324. doi: 10.1016/S0002-9440(10)62558-8
107. Nishimura, M., Abiko, Y., Kurashige, Y., Takeshima, M., Yamazaki, M., Kusano, K., et al. (2004). Effect of defensin peptides on eukaryotic cells: primary epithelial cells, fibroblasts and squamous cell carcinoma cell lines. J. Dermatol. Sci. 36, 87-95. doi: 10.1016/j.jdermsci.2004.07.001
108. Nylandsted, J., Rohde, M., Brand, K., Bastholm, L., Elling, F., and Jaattela, M. (2000). Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2. Proc. Natl. Acad. Sci. U.S.A. 97, 7871-7876. doi: 10.1073/pnas.97.14.7871
109. Oren, Z., and Shai, Y. (1998). Mode of action of linear amphipathic alpha-helical antimicrobial peptides. Biopolymers 47, 451-463. doi: 10.1002/(SICI)1097
110. Ourth, D. D. (2011). Antitumor cell activity in vitro by myristoylated-peptide. Biomed. Pharmacother. 65, 271-274. doi: 10.1016/j.biopha.2011.02.015
111. Papo, N., Braunstein, A., Eshhar, Z., and Shai, Y. (2004). Suppression of human prostate tumor growth in mice by a cytolytic D-, L-amino acid peptide: membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretion. Cancer Res. 64, 5779-5786. doi: 10.1158/0008-5472.CAN-04-1438
112. Papo, N., Seger, D., Makovitzki, A., Kalchenko, V., Eshhar, Z., Degani, H., et al. (2006). Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide. Cancer Res. 66, 5371-5378. doi: 10.1158/0008-5472.CAN-05-4569
113. Papo, N., Shahar, M., Eisenbach, L., and Shai, Y. (2003). A novel lytic peptide composed of DL-amino acids selectively kills cancer cells in culture and in mice. J. Biol. Chem. 278, 21018-21023. doi: 10.1074/jbc.M211204200
114. Papo, N., and Shai, Y. (2005). Host defense peptides as new weapons in cancer treatment. Cell. Mol. Life Sci. 62, 784-790. doi: 10.1007/s00018-005-4560-2
115. Parkin, D. M., Bray, F., Ferlay, J., and Pisani, P. (2005). Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108. doi: 10.3322/canjclin.55.2.74
116. Patra, C. R., Rupasinghe, C. N., Dutta, S. K., Bhattacharya, S., Wang, E. F., Spaller, M. R., et al. (2012). Chemically Modified Peptides Targeting the PDZ Domain of GIPC as a Therapeutic Approach for Cancer. ACS Chem. Biol. 7, 770-779. doi: 10.1021/cb200536r
117. Pelekanou, V., Kampa, M., Gallo, D., Notas, G., Troullinaki, M., Duvillier, H., et al. (2011). The estrogen receptor alpha-derived peptide ER alpha 17p (P-295-T-311) exerts pro-apoptotic actions in breast cancer cells in vitro and in vivo, independently from their ER alpha status. Mol. Oncol. 5, 36-47. doi: 10.1016/j.molonc.2010.11.001
118. Perez-Tomas, R. (2006). Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr. Med. Chem. 13, 1859-1876. doi: 10.2174/092986706777585077
119. Pouny, Y., and Shai, Y. (1992). Interaction of D-amino acid incorporated analogues of pardaxin with membranes. Biochemistry 31, 9482-9490. doi: 10.1021/bi00154a022
120. Qiao, L., and Wong, B. C. Y. (2009). Targeting apoptosis as an approach for gastrointestinal cancer therapy. Drug Resist. Updat. 12, 55-64. doi: 10.1016/j.drup.2009.02.002
121. Reddy, K. V. R., Yedery, R. D., and Aranha, C. (2004). Antimicrobial peptides: premises and promises. Int. J. Antimicrob. Ag. 24, 536-547. doi: 10.1016/j.ijantimicag.2004.09.005
122. Ren, S. X., Shen, J., Cheng, A. S., Lu, L., Chan, R. L., Li, Z. J., et al. (2013). FK-16 derived from the anticancer peptide LL-37 induces caspase-independent apoptosis and autophagic cell death in colon cancer cells. PLoS ONE 8:e63641. doi: 10.1371/journal.pone.0063641
123. Rerole, A. L., Gobbo, J., De Thonel, A., Schmitt, E., De Barros, J. P. P., Hammann, A., et al. (2011). Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy. Cancer Res. 71, 484-495. doi: 10.1158/0008-5472.CAN-10-1443
124. Reya, T., Morrison, S. J., Clarke, M. F., and Weissman, I. L. (2001). Stem cells, cancer, and cancer stem cells. Nature 414, 105-111. doi: 10.1038/35102167
125. Richardson, A., De Antueno, R., Duncan, R., and Hoskin, D. W. (2009). Intracellular delivery of bovine lactoferricin's antimicrobial core (RRWQWR) kills T-leukemia cells. Biochem. Biophys. Res. Commun. 388, 736-741. doi: 10.1016/j.bbrc.2009.08.083
126. Riedl, S., Rinner, B., Asslaber, M., Schaider, H., Walzer, S., Novak, A., et al. (2011a). In search of a novel target - phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy. Biochim. Biophys. Acta 1808, 2638-2645. doi: 10.1016/j.bbamem.2011.07.026
127. Riedl, S., Zweytick, D., and Lohner, K. (2011b). Membrane-active host defense peptides - Challenges and perspectives for the development of novel anticancer drugs. Chem. Phys. Lipids 164, 766-781. doi: 10.1016/j.chemphyslip.2011.09.004
128. Rodrigues, E. G., Dobroff, A. S. S., Cavarsan, C. F., Paschoalin, T., Nimrichter, L., Mortara, R. A., et al. (2008). Effective topical treatment of subcutaneous murine B16F10-Nex2 melanoma by the antimicrobial peptide gomesin. Neoplasia 10, 61-68. doi: 10.1593/neo.07885
129. Rodrigues, E. G., Dobroff, A. S., Taborda, C. P., and Travassos, L. R. (2009). Antifungal and antitumor models of bioactive protective peptides. An. Acad. Bras. Cienc. 81, 503-520. doi: 10.1590/S0001-37652009000300015
130. Rosca, E. V., Koskimaki, J. E., Rivera, C. G., Pandey, N. B., Tamiz, A. P., and Popel, A. S. (2011). Anti-angiogenic peptides for cancer therapeutics. Curr. Pharm. Biotechnol. 12, 1101-1116
131. Schroder-Borm, H., Bakalova, R., and Andra, J. (2005). The NK-lysin derived peptide NK-2 preferentially kills cancer cells with increased surface levels of negatively charged phosphatidylserine. FEBS Lett. 579, 6128-6134. doi: 10.1016/j.febslet.2005.09.084
132. Schweizer, F. (2009). Cationic amphiphilic peptides with cancer-selective toxicity. Eur. J. Pharmacol. 625, 190-194. doi: 10.1016/j.ejphar.2009.08.043
133. Seo, M. D., Won, H. S., Kim, J. H., Mishig-Ochir, T., and Lee, B. J. (2012). Antimicrobial peptides for therapeutic applications: a review. Molecules 17, 12276-12286. doi: 10.3390/molecules171012276
134. Shang, B., Cao, Z., and Zhou, Q. (2012). Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives. Front. Med. 6, 67-78. doi: 10.1007/s11684-012-0176-8
135. Sharma, S. V. (1992). Melittin resistance - a counterselection for ras transformation. Oncogene 7, 193-201.
136. Sinthuvanich, C., Veiga, A. S., Gupta, K., Gaspar, D., Blumenthal, R., and Schneider, J. P. (2012). Anticancer beta-Hairpin peptides: membrane-induced folding triggers activity. J. Am. Chem. Soc. 134, 6210-6217. doi: 10.1021/ja210569f
137. Sok, M., Sentjurc, M., and Schara, M. (1999). Membrane fluidity characteristics of human lung cancer. Cancer Lett. 139, 215-220. doi: 10.1016/S0304-3835(99)00044-0
138. Srisailam, S., Arunkumar, A. I., Wang, W., Yu, C., and Chen, H. M. (2000). Conformational study of a custom antibacterial peptide cecropin B1: implications of the lytic activity. Biochim. Biophys. Acta 1479, 275-285. doi: 10.1016/S0167-4838(00)00008-X
139. Steiner, H., Andreu, D., and Merrifield, R. B. (1988). Binding and action of cecropin and cecropin analogs - antibacterial peptides from insects. Biochim. Biophys. Acta 939, 260-266. doi: 10.1016/0005-2736(88)90069-7
140. Teixeira, V., Feio, M. J., and Bastos, M. (2012). Role of lipids in the interaction of antimicrobial peptides with membranes. Prog. Lipid Res. 51, 149-177. doi: 10.1016/j.plipres.2011.12.005
141. Torfoss, V., Ausbacher, D., Cavalcanti-Jacobsen, C. D., Hansen, T., Brandsdal, B. O., Havelkova, M., et al. (2012a). Synthesis of anticancer heptapeptides containing a unique lipophilic ss 2,2-amino acid building block. J. Pept. Sci. 18, 170-176. doi: 10.1002/psc.1434
142. Torfoss, V., Isaksson, J., Ausbacher, D., Brandsdal, B. O., Flaten, G. E., Anderssen, T., et al. (2012b). Improved anticancer potency by head-to-tail cyclization of short cationic anticancer peptides containing a lipophilic beta(2,2)-amino acid. J. Pept. Sci. 18, 609-619. doi: 10.1002/psc.2441
143. Ueta, E., Tanida, T., and Osaki, T. (2001). A novel bovine lactoferrin peptide, FKCRRWQWRM, suppresses Candida cell growth and activates neutrophils. J. Pept. Res. 57, 240-249. doi: 10.1034/j.1399-3011.2001.057003240.x
144. Utsugi, T., Schroit, A. J., Connor, J., Bucana, C. D., and Fidler, I. J. (1991). Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res. 51, 3062-3066.
145. van Zoggel, H., Carpentier, G., Dos Santos, C., Hamma-Kourbali, Y., Courty, J., Amiche, M., et al. (2012). Antitumor and angiostatic activities of the antimicrobial peptide dermaseptin B2. PLoS ONE 7:e44351. doi: 10.1371/journal.pone.0044351
146. Visse, R., and Nagase, H. (2003). Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 92, 827-839. doi: 10.1161/01.RES.0000070112.80711.3D
147. Wachinger, M., Kleinschmidt, A., Winder, D., Von Pechmann, N., Ludvigsen, A., Neumann, M., et al. (1998). Antimicrobial peptides melittin and cecropin inhibit replication of human immunodeficiency virus 1 by suppressing viral gene expression. J. Gen. Virol. 79, 731-740.
148. Wang, C., Li, H. B., Li, S., Tian, L. L., and Shang, D. J. (2012). Antitumor effects and cell selectivity of temporin-1CEa, an antimicrobial peptide from the skin secretions of the Chinese brown frog (Rana chensinensis). Biochimie 94, 434-441. doi: 10.1016/j.biochi.2011.08.011
149. Wang, C., Tian, L. L., Li, S., Li, H. B., Zhou, Y., Wang, H., et al. (2013a). Rapid cytotoxicity of antimicrobial peptide tempoprin-1CEa in breast cancer cells through membrane destruction and intracellular calcium mechanism. PLoS ONE 8:e60462. doi: 10.1371/journal.pone.0060462
150. Wang, C., Zhou, Y., Li, S., Li, H., Tian, L., Wang, H., et al. (2013b). Anticancer mechanisms of temporin-1CEa, an amphipathic alpha-helical antimicrobial peptide, in Bcap-37 human breast cancer cells. Life Sci. 92, 1004-1014. doi: 10.1016/j.lfs.2013.03.016
151. Wang, G., Li, X., and Wang, Z. (2009a). APD2: the updated antimicrobial peptide database and its application in peptide design. Nucleic Acids Res. 37, D933-D937. doi: 10.1093/nar/gkn823
152. Wang, K. R., Yan, J. X., Zhang, B. Z., Song, J. J., Jia, P. F., and Wang, R. (2009b). Novel mode of action of polybia-MPI, a novel antimicrobial peptide, in multi-drug resistant leukemic cells. Cancer Lett. 278, 65-72. doi: 10.1016/j.canlet.2008.12.027
153. Wang, K. R., Zhang, B. Z., Zhang, W., Yan, J. X., Li, J., and Wang, R. (2008). Antitumor effects, cell selectivity and structure-activity relationship of a novel antimicrobial peptide polybia-MPI. Peptides 29, 963-968. doi: 10.1016/j.peptides.2008.01.015
154. Wang, Y. S., Li, D., Shi, H. S., Wen, Y. J., Yang, L., Xu, N., et al. (2009c). Intratumoral expression of mature human neutrophil peptide-1 mediates antitumor immunity in mice. Clin. Cancer Res. 15, 6901-6911. doi: 10.1158/1078-0432.CCR-09-0484
155. Winder, D., Gunzburg, W. H., Erfle, V., and Salmons, B. (1998). Expression of antimicrobial peptides has an antitumour effect in human cells. Biochem. Biophys. Res. Commun. 242, 608-612. doi: 10.1006/bbrc.1997.8014
156. Wu, J. M., Jan, P. S., Yu, H. C., Haung, H. Y., Fang, H. J., Chang, Y. I., et al. (2009). Structure and function of a custom anticancer peptide, CB1a. Peptides 30, 839-848. doi: 10.1016/j.peptides.2009.02.004
157. Xu, H., Chen, C. X., Hu, J., Zhou, P., Zeng, P., Cao, C. H., et al. (2013). Dual modes of antitumor action of an amphiphilic peptide A(9)K. Biomaterials 34, 2731-2737. doi: 10.1016/j.biomaterials.2012.12.039
158. Yang, Q. Z., Wang, C., Lang, L., Zhou, Y., Wang, H., and Shang, D. J. (2013). Design of potent, non-toxic anticancer peptides based on the structure of the antimicrobial peptide, temporin-1CEa. Arch. Pharm. Res. doi: 10.1007/s12272-12013-0112-8. [Epub ahead of print].
159. Yang, S. T., Shin, S. Y., Lee, C. W., Kim, Y. C., Hahm, K. S., and Kim, J. I. (2003). Selective cytotoxicity following Arg-to-Lys substitution in tritrpticin adopting a unique amphipathic turn structure. FEBS Lett. 540, 229-233. doi: 10.1016/S0014-5793(03)00266-7
160. Yang, W., Luo, D., Wang, S., Wang, R., Chen, R., Liu, Y., et al. (2008). TMTP1, a novel tumor-homing peptide specifically targeting metastasis. Clin. Cancer Res. 14, 5494-5502. doi: 10.1158/1078-0432.CCR-08-0233
161. Yeaman, M. R., and Yount, N. Y. (2003). Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 55, 27-55. doi: 10.1124/pr.55.1.2
162. Yoo, Y. C., Watanabe, S., Watanabe, R., Hata, K., Shimazaki, K., and Azuma, I. (1997). Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Jpn. J. Cancer Res. 88, 184-190. doi: 10.1111/j.1349-7006.1997.tb00364.x
163. Zhang, W., Li, J., Liu, L. W., Wang, K. R., Song, J. J., Yan, J. X., et al. (2010). A novel analog of antimicrobial peptide Polybia-MPI, with thioamide bond substitution, exhibits increased therapeutic efficacy against cancer and diminished toxicity in mice. Peptides 31, 1832-1838. doi: 10.1016/j.peptides.2010.06.019